Keyphrases
Antagonism
100%
Levodopa-induced Dyskinesia
100%
Dopamine Depletion
100%
Kappa Opioid Receptor
100%
L-DOPA
83%
Nor-binaltorphimine (nor-BNI)
83%
Parkinson's Disease
50%
Escalating Dose
50%
Dopamine
33%
Parkinson's Disease Model
33%
Phasic Dopamine
33%
Dose Effect
16%
Compensatory Mechanisms
16%
Motor Impairment
16%
Pathophysiological Mechanisms
16%
Disease States
16%
Dysregulated
16%
Striatal
16%
Striatal Dopamine
16%
Tonic
16%
Development Rate
16%
Functional Restoration
16%
Dopamine Level
16%
Opioid Peptides
16%
Voluntary Movement
16%
Endogenous Ligand
16%
Dependent Development
16%
Dynorphin
16%
Propeptide
16%
Dorsolateral Striatum
16%
6-OHDA Lesion
16%
Kappa Opioid Receptor Antagonist
16%
Pharmacology, Toxicology and Pharmaceutical Science
Levodopa-Induced Dyskinesia
100%
Kappa Opiate Receptor
100%
Parkinson's Disease
83%
DOPA
83%
Disease Model
33%
Motor Dysfunction
16%
Opiate Peptide
16%
Dynorphin
16%
Kappa Antagonists
16%
Neuroscience
Dyskinesia
100%
L-DOPA
100%
Κ-opioid receptor
100%
Parkinson's Disease
45%
Stereotypic Movement Disorder
9%
Striatum
9%
Opioid Peptide
9%
Dynorphin
9%
Kappa Antagonists
9%